» Articles » PMID: 36815647

Nanomaterials As a Potential Target for Infectious Parasitic Agents

Overview
Journal Curr Drug Deliv
Specialty Pharmacology
Date 2023 Feb 23
PMID 36815647
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the technological advancement in the era of personalized medicine and therapeutics development, infectious parasitic causative agents remain one of the most challenging areas of research and development. The disadvantages of conventional parasitic prevention and control are the emergence of multiple drug resistance as well as the non-specific targeting of intracellular parasites, which results in high dose concentration needs and subsequently intolerable cytotoxicity. Nanotechnology has attracted extensive interest to reduce medication therapy adverse effects including poor bioavailability and drug selectivity. Numerous nanomaterials-based delivery systems have previously been shown in animal models to be effective in the treatment of various parasitic infections. This review discusses a variety of nanomaterials-based antiparasitic procedures and techniques as well as the processes that allow them to be targeted to different parasitic infections. This review focuses on the key prerequisites for creating novel nanotechnology-based carriers as a potential option in parasite management, specifically in the context of human-related pathogenic parasitic agents.

Citing Articles

Evaluation of the In-Vitro Effects of Albendazole, Mebendazole, and Praziquantel Nanocapsules against Protoscolices of Hydatid Cyst.

Soleymani N, Sadr S, Santucciu C, Rahdar A, Masala G, Borji H Pathogens. 2024; 13(9).

PMID: 39338980 PMC: 11435210. DOI: 10.3390/pathogens13090790.


Overview of Research on Leishmaniasis in Africa: Current Status, Diagnosis, Therapeutics, and Recent Advances Using By-Products of the Sargassaceae Family.

Mohamed Abdoul-Latif F, Oumaskour K, Abdallah N, Ainane A, Houmed Aboubaker I, Merito A Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675483 PMC: 11054980. DOI: 10.3390/ph17040523.


In vitro evaluation of antileishmanial activity of Boswellia serrata essential oil nanoliposome.

Babaei M, Youssefi M, Nasrabadi N Vet Med Sci. 2024; 10(2):e1400.

PMID: 38379363 PMC: 10879719. DOI: 10.1002/vms3.1400.


Challenges and Prospective of Enhancing Hydatid Cyst Chemotherapy by Nanotechnology and the Future of Nanobiosensors for Diagnosis.

Sadr S, Lotfalizadeh N, Abbasi A, Soleymani N, Hajjafari A, Roohbaksh Amooli Moghadam E Trop Med Infect Dis. 2023; 8(11).

PMID: 37999613 PMC: 10674171. DOI: 10.3390/tropicalmed8110494.

References
1.
Date A, Joshi M, Patravale V . Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev. 2007; 59(6):505-21. DOI: 10.1016/j.addr.2007.04.009. View

2.
Zazo H, Colino C, Lanao J . Current applications of nanoparticles in infectious diseases. J Control Release. 2016; 224:86-102. DOI: 10.1016/j.jconrel.2016.01.008. View

3.
Ma J, Li M, Qi Z, Fu M, Sun T, Elsheikha H . Waterborne protozoan outbreaks: An update on the global, regional, and national prevalence from 2017 to 2020 and sources of contamination. Sci Total Environ. 2021; 806(Pt 2):150562. DOI: 10.1016/j.scitotenv.2021.150562. View

4.
Pensel P, Gamboa G, Fabbri J, Ceballos L, Bruni S, Alvarez L . Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice. Acta Trop. 2015; 152:185-194. DOI: 10.1016/j.actatropica.2015.09.016. View

5.
Amini S . Preparation of antimicrobial metallic nanoparticles with bioactive compounds. Mater Sci Eng C Mater Biol Appl. 2019; 103:109809. DOI: 10.1016/j.msec.2019.109809. View